康弘药业（002773）公告，公司近日收到国家药品监督管理局签发的利非司特滴眼液药品注册证书，批 准注册。利非司特滴眼液适用于治疗干眼的体征和症状，剂型为眼用制剂，规格为5%(0.2ml：10mg)。 该药品为国内首家完成临床研究并获批上市，丰富了公司眼科领域产品管线，提升市场竞争力。 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-037 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和巨潮资讯网（www.cninfo.com.cn）刊登于2025年4月26日《第八届董 事会第十次会议决议公告》（公告编号：2025-010）、《关于使用自有 资金购买理财产品的公告》（公告编号：2025-01 ...

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has completed the registration of changes in its business license and the revision of its articles of association following the approval of relevant proposals at its board and annual shareholder meetings [1][2]. Group 1: Company Actions - The company held its eighth board meeting on April 25, 2025, and the annual shareholder meeting on May 21, 2025, where it approved the proposal to change the registered capital and revise the articles of association [1]. - The revised articles of association are published on the Giant Tide Information Network [1]. Group 2: Documentation - The following documents are available for review: the resolutions from the eighth board meeting, the resolutions from the 2024 annual shareholder meeting, and the revised articles of association as of May 2025 [2].

Core Points - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established on January 19, 2001, and is registered in Chengdu, China [2][3] - The company was approved by the China Securities Regulatory Commission for its initial public offering of 45.6 million shares on June 9, 2015, and was listed on the Shenzhen Stock Exchange on June 26, 2015 [2][3] - The registered capital of the company is RMB 919,869,004 [3] Company Structure - The company operates as a joint-stock limited company with a legal representative being the chairman [3] - The company’s assets are divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [3] - The company has established a Communist Party organization to conduct activities in accordance with the Party's regulations [4] Business Objectives and Scope - The company's business objectives include the research, development, manufacturing, and sales of innovative pharmaceutical products aimed at improving patient health and social medical efficiency [4] - The registered business scope includes the research, production, and sales of pharmaceuticals and medical devices, as well as economic information consulting and import/export of goods and technology [4] Share Structure - The company issues shares in the form of stocks, with each share having a par value of RMB 1 [5] - The total number of shares issued by the company is 919,869,004, all of which are ordinary shares [5][6] - The company does not provide financial assistance to individuals or entities purchasing its shares [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, attend and vote at shareholder meetings, supervise company operations, and access company documents [11][12] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [13] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [46] - Shareholder meetings can be convened by the board of directors or at the request of shareholders holding more than 10% of the shares [51][52] - Decisions at shareholder meetings require a majority or two-thirds majority vote, depending on whether the resolution is ordinary or special [78][80]

成都康弘药业集团股份有限公司 Chengdu Kanghong Pharmaceutical Group Co., Ltd 成都市金牛区蜀西路 108 号 章 程 2025 年 5 月 | 第一章 | 总 则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股 份 | 4 | | 第四章 | 股东和股东大会 | 9 | | 第五章 | | | | | 董事会 | 24 | | 第六章 | 总裁及其他高级管理人员 32 | | | 第七章 | 监事会 | 34 | | 第八章 | 党的建设 | 36 | | 第九章 | 财务会计制度、利润分配和审计 37 | | | 第十章 | 通知和公告 | 40 | | 第十一章 | 合并、分立、增资、减资、解散和清算 41 | | | 第十二章 | 修改章程 44 | | | 第十三章 | 附 则 44 | | 成都康弘药业集团股份有限公司章程 成都康弘药业集团股份有限公司章程 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-036 成都康弘药业集团股份有限公司 序 号 修订前 修订后 1 第六条 公司注册资本为人民币 919,463,954.00 元。 第六条 公司注册资本为人民币 919,869,004.00 元。 2 第二十条 公司的股份总数为 919,463,954 股，全部为普通股。 第二十条 公司的股份总数为 919,869,004 股，全部为普通股。 一、《公司章程》修订的具体情况 二、备查文件 特此公告。 成都康弘药业集团股份有限公司董事会 2025年6月18日 2 / 2 关于完成工商变更登记及公司章程修订的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议、2025 年 5 月 21 日召开 二〇二四年度股东会审议通过了《关于变更公司注册资本及修订〈公 司章程〉的议案》，具体详见公司于 2025 年 4 月 26 日、2025 年 5 月 22 日在《证券时报》《中国证券报》《上海证券报》 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-035 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和巨潮资讯网（www.cninfo.com.cn）刊登于2025年4月26日《第八届董 事会第十次会议决议公告》（公告编号：2025-010）、《关于使用自有 资金购买理财产品的公告》（公告编号：2025-01 ...

Group 1 - Yinlun Co., Ltd. plans to establish a joint venture company, Suzhou Yizhi Lingqiao Drive Technology Co., Ltd., with an investment of 10 million yuan, holding a 20% stake, to enhance the development of embodied intelligent robot components [1] - Zhimin Da's controlling shareholder plans to transfer 5.03 million shares, representing 3.00% of the total share capital, through an inquiry transfer method [1][2] - ST Ningke's subsidiary plans to invest 100 million yuan in a technical transformation project for the production of bio-fermentation products, aiming to enhance market competitiveness [3][4] Group 2 - Fujian Jinsen's chairman resigned due to work reasons, and the resignation will take effect after the election of a new chairman [5][6] - Kanghong Pharmaceutical's subsidiary received approval for clinical trials of Songling Xue Mai Kang capsules, aimed at treating functional ventricular premature beats [7][8] - Ruizhi Pharmaceutical plans to sell a 32.59% stake in its associate company, Guangdong Shenghetang Health Food Co., Ltd., for 60 million yuan [9] Group 3 - Meili Cloud's shareholder, China Metallurgical Paper Group, is undergoing bankruptcy reorganization, with its shares frozen and partially pledged [10] - Mongolian Grass Ecological plans to raise up to 1.495 billion yuan through a private placement for various ecological projects and working capital [11] - Aikelan's major shareholder plans to reduce their stake by up to 3% due to personal funding needs [12] Group 4 - Chaojie Co., Ltd. has three shareholders planning to reduce their stakes by a total of up to 3.73% for personal funding needs [13] - Haitai Biological's director plans to reduce their stake by up to 0.14% for personal funding needs [14] - New Guodu's executives plan to reduce their stakes by a total of up to 50.19 million shares for personal funding needs [15] Group 5 - Zhiguang Electric's vice chairman plans to reduce their stake by up to 304.06 million shares for personal funding needs [16] - *ST Jinbi's controlling shareholder plans to transfer 47.0853 million shares, making Yuan Yi Cheng Wu the new controlling shareholder [17][18] - Kaizhong Precision received a project designation from a leading global new energy battery manufacturer, with expected sales of approximately 700 million yuan [19][20] Group 6 - Defang Nano's director plans to reduce their stake by up to 133,200 shares for personal funding needs [21] - ST Hongtai's stock will have its risk warning removed, changing its name and increasing the price fluctuation limit [22] - Guoanda's directors plan to reduce their stakes by a total of up to 101,700 shares for personal funding needs [23] Group 7 - Lanshi Heavy Industry plans to acquire 100% of Qingdao Equipment for 99.9821 million yuan to enhance its delivery capabilities [24] - Qingdao Bank's major shareholder plans to increase its stake to no more than 19.99%, pending regulatory approval [25]

证券代码：002773 证券简称：康弘药业 公告编号：2025-034 成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）子公 司成都康弘制药有限公司（以下简称"康弘制药"）收到国家药品监督 管理局签发的《药物临床试验批准通知书》。现将相关情况公告如下： 一、药品基本信息 药品名称：松龄血脉康胶囊 剂型：胶囊剂 拟增加功能主治：功能性室性早搏 注册分类：中药 2.3 类 受理号：CXZL2500018 审批结论：同意本品开展用于功能性室性早搏的临床试验。 二、产品简介 松龄血脉康胶囊为我公司独家品种，是我国首个以鲜松叶入药的 降压降脂中成药，已批准功能主治为"平肝潜阳，镇心安神。用于肝 1 / 2 阳上亢所致的头痛、眩晕、急躁易怒、心悸、失眠；高血压及原发性高 脂血症见上述证候者。"。本次新增功能主治临床试验申请的获批， 将有利于进一步提升产品的核心竞争力。 三、对公司的影响 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定 ...

康弘药业(002773.SZ)公告称，公司子公司成都康弘制药有限公司收到国家药品监督管理局签发的《药 物临床试验批准通知书》，同意松龄血脉康胶囊开展用于功能性室性早搏的临床试验。松龄血脉康胶囊 为公司品种，已批准功能主治为"平肝潜阳，镇心安神。用于肝阳上亢所致的头痛、眩晕、急躁易怒、 心悸、失眠； 高血压及原发性高脂血症见上述证候者。" ...